2-{4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxy}acetic acid hydrate

• ChemBase ID: 153113
• Molecular Formular: C24H24O5
• Molecular Mass: 392.44436
• Monoisotopic Mass: 392.16237387
• SMILES: CC/C(=C(/c1ccc(cc1)O)\c1ccc(cc1)OCC(=O)O)/c1ccccc1.O
• Canonical SMILES: CC/C(=C(/c1ccc(cc1)O)\c1ccc(cc1)OCC(=O)O)/c1ccccc1.O
• InChI: InChI=1S/C24H22O4.H2O/c1-2-22(17-6-4-3-5-7-17)24(18-8-12-20(25)13-9-18)19-10-14-21(15-11-19)28-16-23(26)27;/h3-15,25H,2,16H2,1H3,(H,26,27);1H2
• InChIKey: KXJDAHSEWANVPX-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-{4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxy}acetic acid hydrate
• IUPAC Traditional name: 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenoxyacetic acid hydrate
• Synonyms: (E,Z)-2-[4-[1-(p-Hydroxyphenyl)-2-phenyl]-1-butenyl]phenoxyacetic acid; 4-Hydroxytamoxifen acid; (E/Z)-4-HTA monohydrate

Database IDs

• PubChem SID: 24724502; 162247253
• PubChem CID: 16078975

CALCULATED PROPERTIES

• Acid pKa: 3.355508
• H Acceptors: 4
• H Donor: 2
• LogD (pH = 5.5): 3.3768795
• LogD (pH = 7.4): 2.088458
• Log P: 5.506995
• Molar Refractivity: 118.4772 cm^3
• Polarizability: 42.25663 Å^3
• Polar Surface Area: 66.76 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: DMSO: >6 mg/mL
• Apperance: solid

Safety Information

• European Hazard Symbols: Nature polluting (N)
• UN Number: 3077
• German water hazard class: 3
• Hazard Class: 9
• Packing Group: 3
• Risk Statements: 50/53
• Safety Statements: 36/37-60-61
• GHS Pictograms: GHS09
• GHS Signal Word: Warning
• GHS Hazard statements: H410
• GHS Precautionary statements: P273-P501
• Personal Protective Equipment: Eyeshields, Gloves
• RID/ADR: UN 3077 9/PG 3
• Storage Temperature: 2-8°C

Product Information

• Purity: ≥90% (HPLC)
• Empirical Formula (Hill Notation): C24H22O4 · H2O

DETAILS

Sigma Aldrich - H5039

Biochem/physiol Actions
4-hydroxytamoxifen acid is a preferred tamoxifen analog, a nonsteroidal estrogenic compound for use in estrogen replacement therapy, and specifically menopause therapy. The estrogen replacements are administered to patients as the free acid or a pharmaceutically acceptable salt in combination with pharmaceutical carriers to alleviate conditions associated with a low level of estrogen, including osteoporosis, premenstrual syndrome, vasomotor symptoms associated with menopause, atrophic vaginitis, Kraurosis vulvae, female hypogonadism, primary ovarian failure, excessive hair growth and prostatic cancer.